Jackson A, Scarffe J H
Department of Diagnostic Radiology, Stopford Medical School, University of Manchester, UK.
Skeletal Radiol. 1991;20(5):363-7. doi: 10.1007/BF01267664.
Solitary myeloma of bone is a form of plasma cell tumor, histologically indistinguishable from multiple myeloma but characterised by a single bony focus of disease. Most patients respond to local radiotherapy (median survival 10-12 years); however, many (greater than 30%) rapidly develop multiple myeloma (median survival 2-4 years). Currently, no criteria exist for identifying these high-risk patients at the time of diagnosis. We have assessed the prognostic value of clinical features at presentation in 32 patients with solitary myeloma of bone. Only osteopenia at presentation (P less than 0.000003) and immunoparesis (P less than 0.00002) proved to be independent, significant prognosticators of decreased survival. Exclusion of patients with osteopenia or immunoparesis at presentation identified a group with an 80%-90% chance of surviving 10 years. Patients with either risk factor had a median survival of only 27 months. Osteopenia was assessed using measurements of combined cortical thickness in the upper humerus. This site has not previously been used, and normal values are presented for a control group (n = 413).
孤立性骨骨髓瘤是浆细胞肿瘤的一种形式,在组织学上与多发性骨髓瘤无法区分,但特征为单一的骨病灶。大多数患者对局部放疗有反应(中位生存期10 - 12年);然而,许多患者(超过30%)会迅速发展为多发性骨髓瘤(中位生存期2 - 4年)。目前,在诊断时没有识别这些高危患者的标准。我们评估了32例孤立性骨骨髓瘤患者就诊时临床特征的预后价值。仅就诊时的骨质减少(P < 0.000003)和免疫球蛋白减少(P < 0.00002)被证明是生存期缩短的独立、显著的预后指标。排除就诊时骨质减少或免疫球蛋白减少的患者后,确定了一组10年生存率为80% - 90%的患者。有任何一个危险因素的患者中位生存期仅为27个月。骨质减少通过测量肱骨上段皮质厚度总和进行评估。该部位此前未被使用过,本文给出了一个对照组(n = 413)的正常值。